ClinicalTrials.gg
Not yet recruitingNCT07682441Updated Jul 6, 2026

CBITS-RTM Pilot Study

An interventional study of Adapted Cognitive Behavioral Intervention for Trauma in Schools (CBITS) with a Racial Trauma Module (RTM) in PTSD - Post Traumatic Stress Disorder and Substance Use, sponsored by University of California, San Francisco. Not yet recruiting at 1 site in United States. Open to participants aged 13 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by University of California, San Francisco · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
13 Years and older
Sex
All
01

Study summary

This pilot study, conducted in partnership with juvenile detention centers, evaluates an adapted CBITS-RTM intervention delivered in a detention school setting.

Read the detailed description

The study examines the intervention's feasibility and acceptability, as well as its effectiveness in reducing incarcerated youth's posttraumatic stress symptoms, improving academic functioning, and decreasing intentions to use substances post-release.

02

Conditions studied

  • PTSD - Post Traumatic Stress Disorder
  • Substance Use

Keywords

  • Incarcerated youth
  • Juvenile detention school
  • CBITS-RTM
03

In context

Combat Disorders

200 studies on the registry are indexed under Combat Disorders; 90 are open to participants now.

This study's planned enrollment of 28 is below the median of 72 across 167 interventional studies indexed under Combat Disorders.

Browse Combat Disorders studies →

Lead sponsor

University of California, San Francisco is the lead sponsor of 2,169 studies on the registry; 372 are open to participants now.

Of its 267 completed or terminated interventional studies of FDA-regulated products, 202 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
13 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Youth must 1) be currently incarcerated in a partnering juvenile detention center, 2) be between 13-18 years of age, and 3) have a minimum of 3 months remaining on their sentence (i.e., sufficient time required to complete CBITS-RTM). Youth will complete a screening with a study team member involving the 2-item Abbreviated PTSD Checklist-Civilian version, with scores ≥4 considered a positive screen
  • Clinicians are eligible if they are behavioral health staff working with youth at the detention school..

Exclusion criteria

Exclusion Criteria:

  • Observable cognitive or developmental delays or active psychosis that would interfere with completing consent, assessment or intervention.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (estimated)

Study arms

  • Experimental
    Adapted CBITS-RTM Intervention

    Behavioral: Adapted Cognitive Behavioral Intervention for Trauma in Schools (CBITS) with a Racial Trauma Module (RTM)

Interventions

  • BehavioralAdapted Cognitive Behavioral Intervention for Trauma in Schools (CBITS) with a Racial Trauma Module (RTM)

    The Cognitive Behavioral Intervention for Trauma in Schools (CBITS) program is a school-based, group and individual intervention designed to reduce symptoms of post-traumatic stress disorder (PTSD), depression, and behavioral problems, and to improve functioning, grades and attendance, and coping skills. The CBITS intervention was adapted to juvenile justice settings with an added Racial Trauma Module (RTM), which provides youth with an overview of the effects of racism on levels of traumatic stress.

    Also known as: CBITS-RTM

06

What researchers measure

Primary outcomes

  1. Child PTSD Symptom Scale (CPSS)

    The CPSS is used to measure posttraumatic stress among youth (8-18 years). It assesses past month posttraumatic stress symptom severity and impairment of endorsed symptoms on daily functioning. Scores range from 0-80, with 31+ indicating probable PTSD.

    Time frame: Baseline, 3 months post-baseline

Secondary outcomes

  1. Youth Alcohol and Drug Use Survey

    The Youth Alcohol and Drug Use Survey will be used to gather youth's intention to use substances post-release using items rated on a scale from 1 (unlikely) to 10 (very likely).

    Time frame: Baseline, 3 months post-baseline

  2. Texas Christian University (TCU) Drug Screen

    The TCU will be administered to gather information on substance use quantity and frequency as well as risk for SUD (corresponds with DSM-5 criteria) on the 3-months prior to incarceration and past 3 months at post-release.

    Time frame: Baseline, 3-months post-baseline

Other outcomes

  1. Youth Background Characteristics

    Demographics questionnaire used to gather standard demographics (e.g., age, gender, race) and information such as state agency involvement (e.g., age at first contact with juvenile legal system, number of prior arrests), immigration status.

    Time frame: Baseline

  2. Treatment Acceptability Form

    This form will be used to assess the acceptability of the adapted CBITS-RTM intervention. Items are scored from 1 "Strongly disagree" to 5 "Strongly agree." Scores range from 10-50 with higher scores indicating higher acceptability.

    Time frame: 3-months post-baseline

  3. CBITS-RTM Group Evaluation Posttest

    This will assess knowledge of trauma, changes in ability to cope with stress, and acceptability of the intervention and its delivery. Items are true/false or qualitative in nature.

    Time frame: 3-months post-baseline

  4. Clinician personal and professional background characteristics

    Questionnaire used to gather personal and professional background characteristics (e.g., clinical discipline, experience with trauma treatment, years of practice in juvenile detention setting).

    Time frame: Baseline

  5. Cognitive Behavioral Intervention for Trauma in Schools-Fidelity Adherence Measure 2.0

    This measure will be used to assess how closely clinicians adhere to the adapted CBITS-RTM intervention. The scale describes the core components expected to be covered in each session, and the rater indicates the degree to which each component was delivered with fidelity using a 4-point item rating ranging from 0 (not covered at all) to 3 (covered thoroughly). Higher item scores indicate greater fidelity to the intervention curriculum.

    Time frame: 20% of the sessions

  6. The Evidence-Based Practice Attitude Scale (EBPAS)

    The EBPAS (15-items) will be used to assess clinician's attitudes toward adopting new evidence-based practices (EBPs). It consists of four subscales: appeal, requirements, openness, and divergence. Items are rated on a 5-point Likert scale from 0 (not at all) to 4 (to a very great extent). Higher scores on the Appeal, Requirements, and Openness subscales indicate more positive attitudes toward adopting EBPs, whereas higher Divergence scores indicate less favorable attitudes.

    Time frame: Baseline

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jun 2027, 9 months later.

Of 73 non-industry interventional studies with no phase under Combat Disorders, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 44. This study's planned 9 months is below that.

Counting every sponsor, half of 79 studies reached it within 25 months; a quarter within 12 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Jul 2, 2026
StartEst.
Sep 1, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07682441
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Sep 1, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Johanna B Folk, PhD
Contact
johanna.folk@ucsf.edu
415-602-9521
Jeanne McPhee, PhD
Contact
jeanne.mcphee@ucsf.edu
Johanna Folk, PhD
principal investigator · University of California, San Francisco

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion